Chiesi Completes the Acquisition of Three Hospital Products — Kengreal(R), Cleviprex(R) and Argatroban(TM) for Injection

“Kengreal and Cleviprex significantly expand our hospital portfolio in the United States, and this is why we chose to target them,” said Ugo Di Francesco, CEO of Chiesi Farmaceutici S.p.A., Chiesi USA’s parent company. “Acquiring these products fits with our global strategy of reinvesting in our businesses to help patients and to grow our company.”

“Chiesi USA continues to be a primary focus for investment,” Di Francesco added. “Our team is actively working to identify and evaluate other acquisition opportunities and we intend to continue to expand our business in the United States.”

Ken McBean, President and Chief Executive Officer of Chiesi USA, said, “Our acquisition of these products further strenghtens our position as a leader in the hospital and adjacent specialty product space. We are excited to be able to offer these products to healthcare providers to enhance care for their patients who can benefit from these medications.”

Headquartered in Parma, Italy Chiesi Farmaceutici is an international research-focused Healthcare group, with over 80 years of experience in the pharmaceutical industry. Chiesi researches, develops and markets innovative drugs in the respiratory therapeutics, specialist medicine and rare diseases areas. Its R&D centers in Parma (Italy), Paris (France), Cary (USA), Chippenham (UK) and the R&D team of the acquired Danish company Zymenex, integrate their efforts to advance Chiesi’s pre-clinical, clinical and registration programs. Chiesi employs over 4,500 people, 560 of whom are solely dedicated to Research and Development activities.

PP-MULTI-005 V2.0